Ultragenyx Pharmaceutical Dirección

Dirección controles de criterios 2/4

El CEO de Ultragenyx Pharmaceutical's es Emil Kakkis , nombrado en Apr 2010, tiene una permanencia de 14.08 años. compensación anual total es $12.14M, compuesta por 6.6% salario y 93.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.28% de las acciones de la empresa, por valor de $115.89M. La antigüedad media del equipo directivo y de la junta directiva es de 8.4 años y 8.1 años, respectivamente.

Información clave

Emil Kakkis

Chief Executive Officer (CEO)

US$13.1m

Compensación total

Porcentaje del salario del CEO	6.3%
Permanencia del CEO	14.1yrs
Participación del CEO	2.6%
Permanencia media de la dirección	8.4yrs
Promedio de permanencia en la Junta Directiva	8.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Emil Kakkis en comparación con los beneficios de Ultragenyx Pharmaceutical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$613m
Dec 31 2023	US$13m	US$824k	-US$607m
Sep 30 2023	n/a	n/a	-US$635m
Jun 30 2023	n/a	n/a	-US$721m
Mar 31 2023	n/a	n/a	-US$719m
Dec 31 2022	US$12m	US$796k	-US$707m
Sep 30 2022	n/a	n/a	-US$678m
Jun 30 2022	n/a	n/a	-US$506m
Mar 31 2022	n/a	n/a	-US$470m
Dec 31 2021	US$10m	US$769k	-US$454m
Sep 30 2021	n/a	n/a	-US$356m
Jun 30 2021	n/a	n/a	-US$351m
Mar 31 2021	n/a	n/a	-US$204m
Dec 31 2020	US$5m	US$759k	-US$187m
Sep 30 2020	n/a	n/a	-US$256m
Jun 30 2020	n/a	n/a	-US$301m
Mar 31 2020	n/a	n/a	-US$425m
Dec 31 2019	US$7m	US$714k	-US$403m
Sep 30 2019	n/a	n/a	-US$397m
Jun 30 2019	n/a	n/a	-US$371m
Mar 31 2019	n/a	n/a	-US$325m
Dec 31 2018	US$5m	US$680k	-US$198m
Sep 30 2018	n/a	n/a	-US$192m
Jun 30 2018	n/a	n/a	-US$183m
Mar 31 2018	n/a	n/a	-US$204m
Dec 31 2017	US$7m	US$638k	-US$302m

Compensación vs. Mercado: La compensación total de Emil($USD12.14M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD2.61M).

Compensación vs. Ingresos: La compensación de Emil ha aumentado mientras la empresa no es rentable.

CEO

Emil Kakkis (63 yo)

14.1yrs

Permanencia

US$13,077,993

Compensación

Dr. Emil D. Kakkis, MD, Ph D., is Venture Advisor of Forge Life Science Partners. He is Founder for Ultragenyx Pharmaceutical Inc. He has been the Chief Executive Officer and President of Ultragenyx Pharma...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Emil Kakkis	Founder	14.1yrs	US$13.08m	2.64% $ 91.0m
Howard Horn	Executive VP of Corporate Strategy & CFO	less than a year	US$5.94m	sin datos
Karah Parschauer	Chief Legal Officer & Executive VP of Corporate Affairs	7.9yrs	US$4.04m	0.030% $ 1.0m
John Pinion	Chief Quality Operations Officer & Executive VP of Translational Sciences	8.8yrs	US$4.05m	0.056% $ 1.9m
Erik Harris	Executive VP & Chief Commercial Officer	no data	US$4.07m	0.028% $ 951.1k
Theodore Huizenga	Senior VP	10.3yrs	sin datos	0.021% $ 721.2k
Ernie Meyer	Chief Human Resources Officer & Executive VP	3.7yrs	sin datos	sin datos
Thomas Kassberg	Chief Business Officer & Executive VP	12.5yrs	US$2.46m	0.25% $ 8.7m
Vimal Srivastava	Senior Vice President of Business Development & Alliance Management	6.2yrs	sin datos	sin datos
Dennis Huang	Chief Technical Operations Officer and EVP of Gene Therapy Research & Development	9yrs	US$4.24m	0.049% $ 1.7m
Aaron Olsen	Senior Vice President of Corporate Strategy & Finance	no data	sin datos	sin datos
Eric Crombez	Chief Medical Officer & Executive VP	less than a year	sin datos	0.022% $ 763.7k

8.4yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0LIF es experimentado (8.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Emil Kakkis	Founder	14.1yrs	US$13.08m	2.64% $ 91.0m
Daniel Welch	Independent Non-Executive Chairman	9.1yrs	US$499.89k	0.026% $ 898.0k
Matthew Fust	Independent Director	10.3yrs	US$479.89k	0.018% $ 617.6k
Shehnaaz Suliman	Independent Director	5.3yrs	US$466.89k	0.018% $ 617.3k
Deborah Dunsire	Independent Director	7.1yrs	US$459.89k	0.019% $ 659.4k
Corazon Sanders	Independent Director	2.9yrs	US$469.39k	0.0092% $ 319.3k
Michael Narachi	Independent Director	9.3yrs	US$482.39k	0.026% $ 898.0k
Amrit Ray	Independent Director	2.1yrs	US$460.39k	0.013% $ 439.5k

8.1yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de 0LIF se considera experimentada (8 años de antigüedad promedio).

Ultragenyx Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Ultragenyx Pharmaceutical Inc., Annual General Meeting, Jun 18, 2024

Independent Director recently sold US$620k worth of stock

Ultragenyx Pharmaceutical Inc. Announces Appointment of Howard Horn as Chief Financial Officer, Effective October 16, 2023

Chief Medical Officer & Executive VP recently sold US$176k worth of stock

Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Executive Vice President

Executive VP & CFO recently sold US$133k worth of stock

Recent updates

New major risk - Financial position

First quarter 2024 earnings released: US$2.03 loss per share (vs US$2.33 loss in 1Q 2023)

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024

Ultragenyx Pharmaceutical Inc. Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

New minor risk - Share price stability

Ultragenyx Pharmaceutical Inc., Annual General Meeting, Jun 18, 2024

Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

Independent Director recently sold US$620k worth of stock

Full year 2023 earnings released: US$8.25 loss per share (vs US$10.12 loss in FY 2022)

Ultragenyx Pharmaceutical Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Full year 2023 earnings released: US$8.25 loss per share (vs US$10.12 loss in FY 2022)

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024

Ultragenyx Pharmaceutical Inc. Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx Pharmaceutical Inc. Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

New major risk - Financial position

Mereo Biopharma Group plc Provides Update on Pipeline Progress and Corporate Developments

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2024

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$2.23 loss per share (vs US$3.50 loss in 3Q 2022)

Ultragenyx Pharmaceutical Inc. Announces Program and Pipeline Updates At Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (Oi), Angelman Syndrome (As) and Wilson Disease

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc. Launches Evkeeza (Enacumab for Injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

New minor risk - Financial position

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$2.25 loss per share (vs US$2.26 loss in 2Q 2022)

Ultragenyx Pharmaceutical Inc. Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Ultragenyx Pharmaceutical Inc. Announces Appointment of Howard Horn as Chief Financial Officer, Effective October 16, 2023

Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell Small Cap Comp Value Index

Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study

Ultragenyx Pharmaceutical Inc. Announces U.S. Food and Drug Administration Reviews and Agrees to Protocol Amendment to the Phase 1/2 Study of GTX-102

Ultragenyx Pharmaceutical Inc. Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2023 Annual Meeting

First quarter 2023 earnings released: US$2.33 loss per share (vs US$2.19 loss in 1Q 2022)

Ultragenyx Pharmaceutical Inc. Reaffirms Earning Guidance for the Full Year 2023

Chief Medical Officer & Executive VP recently sold US$176k worth of stock

Full year 2022 earnings released: US$10.12 loss per share (vs US$6.70 loss in FY 2021)

Ultragenyx Pharmaceutical Inc. Reaffirms Full Year Earnings Guidance for the Year 2023

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for the Year 2022 and 2023

Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Executive Vice President

Third quarter 2022 earnings released: US$3.50 loss per share (vs US$1.08 loss in 3Q 2021)

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2022

Executive VP & CFO recently sold US$133k worth of stock

Second quarter 2022 earnings released: US$2.26 loss per share (vs US$1.81 loss in 2Q 2021)

Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) acquired GeneTx Biotherapeutics LLC from Foundation for Angelman Syndrome Therapeutics and others for $190 million.

Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) acquired GeneTx Biotherapeutics LLC from Foundation for Angelman Syndrome Therapeutics and others for $190 million.

Ultragenyx Pharmaceutical Inc. Announces Positive Longer-Term Durability Data from Two Phase 1/2 Gene Therapy Studies

First quarter 2022 earnings released: US$2.19 loss per share (vs US$2.03 loss in 1Q 2021)

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for the Financial Year 2022

Ultragenyx Pharmaceutical Inc. Announces the Appointment of Amrit Ray to Board of Directors

Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta

Insufficient new directors

Ultragenyx Pharmaceutical Inc. Reaffirms Revenue Guidance for the Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Insufficient new directors

Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for the Year 2022

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. Provides Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome

Ultragenyx Pharmaceutical Inc. Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III

Ultragenyx Pharmaceutical Inc. Announces New Long-Term Durability Data from Phase 1/2 Studies of DTX401 for Glycogen Storage Disease Type Ia and DTX301 for Ornithine Transcarbamylase Deficiency

Third quarter 2021 earnings released: US$1.08 loss per share (vs US$1.13 loss in 3Q 2020)

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S

Ultragenyx Pharmaceutical Inc. Announces Mepsevii® (Vestronidase Alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

Ultragenyx Canada Announces Health Canada Approval of Second Indication for Crysvita™ (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults

Second quarter 2021 earnings released: US$3.62 loss per share (vs US$0.42 profit in 2Q 2020)

Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 2000 Growth Index

GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome

Forecast to breakeven in 2025

GeneTx and Ultragenyx Receive Clearance from Health Canada to Begin Clinical Study of GTX-102 in Canada for the Treatment of Angelman Syndrome